Navigation Links
ARIUS presents new findings for anti-cancer antibody programs at AACR
Date:4/15/2008

nstrated that treatment with ARIUS' CD9 targeting antibody, AR40A746.2.3, induced apoptosis in BxPC-3 pancreatic cancer cell as a monotherapy. Moreover, apoptosis is achieved through inhibition of the AKT pathway, commonly believed to be an important pathway for cancer cell survival.

New immunohistochemistry (IHC) studies using this antibody showed that CD9 is expressed in a variety of human tumor samples, resulting in moderate to high levels of staining in 61/82 (73.5%) of tumor cells from various organs including pancreas, prostate, stomach and liver. The antibody demonstrated potent anti-tumor efficacy in in vivo models of pancreatic, breast and AML cancers and treatment led to a decrease in phosphorylation of several receptor tyrosine kinases.

CD9 is highly and differentially expressed in AML versus normal CD34+CD38- stem cells. Experiments strongly suggest that ARIUS' CD9 targeting antibody inhibits human AML outgrowth in pre-clinical studies. In secondary transplantation experiments, treatment with ARIUS' CD9 targeting antibody dramatically reduced the self-renewal capacity of AML cancer stem cells. CD9 is the first description of a marker that is differentially expressed on cancer versus normal stem cells.

Trop-2 Signal Transduction Program

AR47A6.4.2, a naked monoclonal antibody targeting Trop-2, exhibits anti-tumor efficacy in multiple human cancer models as a monotherapeutic agent and demonstrates efficacy in combination therapy. Abstract Number 3990. Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

ARIUS shows its Trop-2 targeting antibody, AR47A6.4.2, is involved in the MAPK pathway. This antibody demonstrated potent anti-tumor efficacy in human pancreatic, breast, colon and prostate cancer models. In combination with Gemcitabine, this antibody also inhibited tumor growth by 93% in a human pancreatic cancer model. ARIUS' Trop-2 targeting antibody is the only naked therapeutic antibody targeti
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ARIUS announces first quarter fiscal 2008 financial results
2. ARIUS 2008 Annual and Special Meeting of Shareholders
3. ARIUS recognized for entrepreneurial excellence
4. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
5. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
6. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
7. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
8. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
9. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
10. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
11. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... | RBJ today announces the firm brokered a long-term lease ... leading biopharmaceutical company, at Two Ledgemont Center in ... , president, and Brian Cohen , senior vice president, ... at 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... 21, 2015 Cambridge Semantics, the leading provider ... announced that 2014 was a record-breaking year across the board ... the Anzo Smart Data Platform and our Smart Data solutions, ... from diverse data which led to record growth for the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Crystal Diagnostics (CDx) ... that it has received AOAC-PTM Certifications for the six non-O157 ... and O145; collectively referred to as STEC or the “Big-6”) ... colony forming unit (cfu) per 325 g of raw ground ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Cambridge Semantics Announces Record Results for 2014 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2
... Inc. (Nasdaq: NVAX ) a clinical-stage vaccine company, ... be presenting at the Cowen and Company 29th Annual Healthcare ... at the Boston Marriott Copley Place in Boston, MA. Dr. ... and development progress. A link to the live presentation ...
... YORK, March 13 Jina Ventures is pleased ... Swiss Pharma Contract (SPC) by leading contract research ... Jina Ventures was the exclusive financial advisor ... facilities and services of Basel, Switzerland area-based SPC."We are thrilled ...
... PRINCETON, N.J., March 13 Covance Inc. (NYSE: ... is expanding its clinical pharmacology footprint in Europe ... 50-bed clinical research company based in Basel, Switzerland."Our ... that can help them make decisions faster is ...
Cached Biology Technology:Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc 2Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site 2
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight ... watermarking and fingerprinting markets. Watermarking aims to control ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... Inc., a privately-held company dedicated to maternal and fetal ... nd Annual Meeting of the American Society of ... San Francisco, California. (Logo: http://photos.prnewswire.com/prnh/20120425/SF94380LOGO ) ... access to a blood test that is safe, early ...
... to make cordite, the explosive propellant that replaced gunpowder ... new use in the production of advanced biofuels. With ... U.S. Department of Energy (DOE),s Lawrence Berkeley National Laboratory ... butanol and ethanol from lignocellulosic biomass could be selectively ...
... is a natural battery a chamber filled with ions ... today,s issue of the journal Nature Biotechnology , a ... Infirmary (MEEI) and the Harvard-MIT Division of Health Sciences and ... could power implantable electronic devices without impairing hearing. The ...
Cached Biology News:Verinata Health Announces New Findings At The American Society Of Human Genetics 2More bang for the biofuel buck 2More bang for the biofuel buck 3More bang for the biofuel buck 4Medical devices powered by the ear itself 2Medical devices powered by the ear itself 3
Recombinant Mouse MMP-9, CF...
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
... High Sensitivity Freezing Point Osmometer for 10 L sample. Ideal for small volume applications, including pediatric, ... Ready to run in less than 3 minutes after turn-on. ... ... ...
Biology Products: